AU2023229084A1 - Methods of treating cancer with iap antagonist compounds and combination therapies - Google Patents

Methods of treating cancer with iap antagonist compounds and combination therapies Download PDF

Info

Publication number
AU2023229084A1
AU2023229084A1 AU2023229084A AU2023229084A AU2023229084A1 AU 2023229084 A1 AU2023229084 A1 AU 2023229084A1 AU 2023229084 A AU2023229084 A AU 2023229084A AU 2023229084 A AU2023229084 A AU 2023229084A AU 2023229084 A1 AU2023229084 A1 AU 2023229084A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023229084A
Other languages
English (en)
Inventor
Gautam Borthakur
Martin John Sims
Tomoko SMYTH
George Albert Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
University of Texas System
Original Assignee
Taiho Pharmaceutical Co Ltd
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, University of Texas System, University of Texas at Austin filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2023229084A1 publication Critical patent/AU2023229084A1/en
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, TAIHO PHARMACEUTICAL CO., LTD. reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Request for Assignment Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, OTSUKA PHARMACEUTICAL CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023229084A 2022-03-04 2023-03-03 Methods of treating cancer with iap antagonist compounds and combination therapies Pending AU2023229084A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316680P 2022-03-04 2022-03-04
US63/316,680 2022-03-04
PCT/US2023/063669 WO2023168394A1 (en) 2022-03-04 2023-03-03 Methods of treating cancer with iap antagonist compounds and combination therapies

Publications (1)

Publication Number Publication Date
AU2023229084A1 true AU2023229084A1 (en) 2024-10-17

Family

ID=85792184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023229084A Pending AU2023229084A1 (en) 2022-03-04 2023-03-03 Methods of treating cancer with iap antagonist compounds and combination therapies

Country Status (7)

Country Link
US (1) US20250186451A1 (https=)
EP (1) EP4486352A1 (https=)
JP (1) JP2025508016A (https=)
KR (1) KR20240156407A (https=)
AU (1) AU2023229084A1 (https=)
TW (1) TW202345849A (https=)
WO (1) WO2023168394A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
CN120379671A (zh) * 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
KR20240156407A (ko) 2024-10-29
US20250186451A1 (en) 2025-06-12
TW202345849A (zh) 2023-12-01
JP2025508016A (ja) 2025-03-21
EP4486352A1 (en) 2025-01-08
WO2023168394A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7206314B2 (ja) Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
CN114025844B (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
AU2022203810B2 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
JP5411847B2 (ja) Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
IL272277A (en) Benzoxazepin oxazolidinone compounds and methods of use
KR20180005178A (ko) 치환된 퀴나졸린 화합물 및 이의 사용방법
WO2015184305A1 (en) TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US20250186451A1 (en) Methods of treating cancer with iap antagonist compounds and combination therapies
JP2018519304A (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
JP2022552880A (ja) 置換４－アミノイソインドリン－１，３－ジオン化合物および組合せ使用のための第２の活性剤
WO2024047394A1 (en) Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
WO2024227033A1 (en) Heterocyclic compounds as parp1 inhibitors
HK40122816A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
ES2702698T3 (es) Polimorfo del derivado de dihidropirazolopirimidinona como inhibidor de la cinasa Wee1
HK40049323A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
BR122021024771B1 (pt) Uso de uma combinação de inibidores de jak1/2e pi3ksigma no tratamento de mielofibrose
BR112016023322B1 (pt) Uso de uma combinação de inibidores de jak e pi3ksigma
HK1233180B (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK1233180A1 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER APPLICANT(S): OTSUKA PHARMACEUTICAL CO., LTD.; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Owner name: TAIHO PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): OTSUKA PHARMACEUTICAL CO., LTD.; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM